3,4,6-tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-α,β-L-gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,4,6-tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-α,β-L-gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate
• 英文别名: 3,4,6-tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-α,β-L-gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate；2-[2-(benzyloxycarbonylamino)ethyloxy]ethyl 3,4,6-tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-α,β-L-gulopyranoside；[(2S,3R,4S,5S)-3,4-diacetyloxy-5-[(2R,3S,4S,5R,6R)-4,5-diacetyloxy-6-(acetyloxymethyl)-3-carbamoyloxyoxan-2-yl]oxy-6-[2-[2-(phenylmethoxycarbonylamino)ethoxy]ethoxy]oxan-2-yl]methyl acetate
• 化学式: C₃₇H₅₀N₂O₂₁
• 分子量: 858.805
• InChiKey: OMIDFRDSINUQQX-IBCOVNOKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  60
• 可旋转键数：
  28
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  295
• 氢给体数：
  2
• 氢受体数：
  21

反应信息

• 作为反应物：
  描述：

  3,4,6-tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-α,β-L-gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate 在 甲醇 、 sodium methylate 、 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 (2-O-carbamoyl-α-D-mannopyranosyl)-α,β-L-gulopyranosyl 2-(2-aminoethoxy)ethanol
  参考文献：
  名称：

  [EN] SUGAR-LINKER-DRUG CONJUGATES
  [FR] CONJUGUÉS DE MÉDICAMENT-SÉQUENCE DE LIAISON DU SUCRE

  摘要：

  本公开涉及糖-连接剂-药物共轭物，其化学式为[A-B-]n-L-D，其中A是一种糖类；B是一个间隔物，n是从1到3中选择的整数；L是一个连接基团，D是一种具有从一次或二次胺、羟基、硫醇、羧基、醛基和酮基中选择的化学反应性官能团的药物。还提供了包括这些共轭物的药物组合物和使用方法。

  公开号：

  WO2014145109A1
• 作为产物：
  描述：

  L-xylopyranose 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 三氟甲磺酸三甲基硅酯 、 palladium 10% on activated carbon 、 10 wt% Pd(OH)2 on carbon 、 氨 、 氢气 、 乙酸肼 、 sodium hydride 、 溶剂黄146 、 三乙胺 、 三氟甲烷磺酸甲酯 、 mercury(II) oxide 、 magnesium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 、 mineral oil 为溶剂， -20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 31.59h， 生成 3,4,6-tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-α,β-L-gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate
  参考文献：
  名称：

  [EN] SACCHARIDE CONJUGATES
  [FR] CONJUGUÉS SACCHARIDIQUES

  摘要：

  这项发明涉及包含糖苷共轭到成像剂或报告基团的化合物，包含它们的组合物以及使用它们的方法。具体提供了含有不同连接基团和成像剂或报告基团的BLM-二糖和BLM-单糖共轭物，用于靶向和成像肿瘤。

  公开号：

  WO2014152718A1

文献信息

• [EN] SACCHARIDE CONJUGATES<br/>[FR] CONJUGUÉS SACCHARIDIQUES
  申请人：UNIV ARIZONA

  公开号：WO2014152718A1

  公开（公告）日：2014-09-25

  This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.

  这项发明涉及包含糖苷共轭到成像剂或报告基团的化合物，包含它们的组合物以及使用它们的方法。具体提供了含有不同连接基团和成像剂或报告基团的BLM-二糖和BLM-单糖共轭物，用于靶向和成像肿瘤。
• SACCHARIDE CONJUGATES
  申请人：ARIZONA BOARD OF REGENTS, for and on behalf of ARIZONA STATE UNIVERSITY

  公开号：US20160038615A1

  公开（公告）日：2016-02-11

  This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.

  本发明涉及包含糖链与成像剂或报告基团偶联的化合物、包含它们的组合物以及使用它们的方法。具体提供了含有不同连接基团和成像剂或报告基团的BLM-双糖和BLM-单糖共轭物，用于靶向和成像肿瘤。
• SUGAR-LINKER-DRUG CONJUGATES
  申请人：ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITY

  公开号：US20160045611A1

  公开（公告）日：2016-02-18

  The present disclosure relates to sugar-linker-drug conjugates, of the formula [A-B-]n-L-D, wherein A is a saccharide; B is a spacer, n is an integer selected from 1 to 3; L is a linker group and D is a drug having a chemically reactive functional group selected from the group consisting of a primary or secondary amine, hydroxyl, sulfhydryl, carboxyl, aldehyde and ketone. Pharmaceutical compositions comprising the conjugates and methods of using them are also provided.

  本公开涉及糖链连接药物偶联物，其化学式为[A-B-]n-L-D，其中A为糖类；B为间隔物，n为从1到3选择的整数；L为连接基团，D为具有化学反应性官能团的药物，所述官能团选择自一级或二级胺、羟基、硫醇、羧基、醛和酮的群组。还提供了包含该偶联物的制药组合物以及使用它们的方法。
• [EN] SUGAR-LINKER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS DE MÉDICAMENT-SÉQUENCE DE LIAISON DU SUCRE
  申请人：UNIV ARIZONA

  公开号：WO2014145109A1

  公开（公告）日：2014-09-18

  The present disclosure relates to sugar-linker-drug conjugates, of the formula [A-B-]n-L-D, wherein A is a saccharide; B is a spacer, n is an integer selected from 1 to 3; L is a linker group and D is a drug having a chemically reactive functional group selected from the group consisting of a primary or secondary amine, hydroxyl, sulfhydryl, carboxyl, aldehyde and ketone. Pharmaceutical compositions comprising the conjugates and methods of using thern are also provided.

  本公开涉及糖-连接剂-药物共轭物，其化学式为[A-B-]n-L-D，其中A是一种糖类；B是一个间隔物，n是从1到3中选择的整数；L是一个连接基团，D是一种具有从一次或二次胺、羟基、硫醇、羧基、醛基和酮基中选择的化学反应性官能团的药物。还提供了包括这些共轭物的药物组合物和使用方法。
• Modified Bleomycin Disaccharides Exhibiting Improved Tumor Cell Targeting
  作者：Manikandadas M. Madathil、Chandrabali Bhattacharya、Zhiqiang Yu、Rakesh Paul、Michael J. Rishel、Sidney M. Hecht

  DOI：10.1021/bi501102z

  日期：2014.11.4

  The bleomycins (BLMs) are a family of antitumor antibiotics used clinically for anticancer chemotherapy. Their antitumor selectivity derives at least in part from their ability to target tumor cells, a property that resides in the carbohydrate moiety of the antitumor agent. In earlier studies, we have demonstrated that the tumor cell selectivity resides in the mannose carbamoyl moiety of the BLM saccharide and that both the BLM disaccharide and monosaccharide containing the carbamoyl moiety were capable of the delivery/uptake of a conjugated cyanine dye into cultured cancer cell lines. Presently, the nature of the participation of the carbamoyl moiety has been explored further to provide compounds of utility for defining the nature of the mechanism of tumor cell recognition and uptake by BLM saccharides and in the hope that more efficient compounds could be identified. A library of seven disaccharide-Cy5** dye conjugates was prepared that are structural analogues of the BLM disaccharide. These differed from the natural BLM disaccharide in the position, orientation, and substitution of the carbamoyl group. Studies of these compounds in four matched sets of tumor and normal cell lines revealed a few that were both tumor cell selective and internalized 2-4-fold more efficiently than the natural BLM disaccharide.